Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.

Start Date29 Nov 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06912763

/ Not yet recruitingPhase 2IIT

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

Start Date18 Sep 2025

Sponsor / Collaborator-

NCT06998628

/ RecruitingPhase 2IIT

Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints

Start Date02 Jul 2025

Sponsor / Collaborator

Tanta University

100 Clinical Results associated with Pentoxifylline

100 Translational Medicine associated with Pentoxifylline

100 Patents (Medical) associated with Pentoxifylline

7,651

Literatures (Medical) associated with Pentoxifylline

01 Oct 2025·TISSUE & CELL

Targeting the p38MAPK/STAT3/NF-κB65 pathway modulates the hepatoprotective effect of pentoxifylline against sodium valproate-induced liver injury in rats; A study based on integrating network pharmacology and experiment validation

Article

Author: Alaa Mohamed Kamel, Gellan ; Hussein, Shaimaa

Sodium valproate (SVP) is frequently utilized in the treatment of epilepsy. Extended administration of SVP elevates the likelihood of hepatotoxicity. Pentoxifylline (PTX) functions as a nonselective phosphodiesterase inhibitor and is commonly utilized in the treatment of vascular conditions, exhibiting extensive antioxidant and anti-inflammatory properties. This research examined PTX's protective role in mitigating SVP-induced liver injury, clarifying the potential molecular mechanisms involved. SVP and PTX intersection targets were identified through network pharmacology. In addition, we conducted an in vivo experiment utilizing the SVP-induced liver injury model. Eighteen adult male rats were allocated to three groups, with the control group receiving oral normal saline. The SVP group was administered SVP (dissolved in normal saline) daily for 2 weeks. The PTX + SVP group was administered SVP in conjunction with PTX daily for two weeks. PTX hepatoprotective effect against SVP could include apoptosis, anti-inflammatory mechanisms, and various signaling pathways, such as NF-κB, STAT3, and MAPK, as indicated by the KEGG and GO enrichment analysis of the 272 common targets. We identified BCL2, IL6, and TNF as potential hub targets of PTX for liver injury treatment based on the construction of the PPI network. In vivo experiments demonstrated that PTX hindered MAPK P38/STAT3/NF-κB-related pathways' activation, diminished oxidative stress, apoptosis, and inflammatory response, and substantially ameliorated SVP-induced liver injury. The network pharmacology study concluded that the MAPK P38/STAT3/NF-κB pathway plays a role in PTX protective effect against SVP-induced liver injuries, as demonstrated by the in vivo experiment results.

01 Sep 2025·ENVIRONMENTAL POLLUTION

Validation of a large volume-solid phase extraction methodology for biotoxicity assessment of pharmaceuticals in aquatic organisms

Article

Author: Gómez-Canela, Cristian ; Moragrega-Knol, Emma ; Barata, Carlos ; Romero-Alfano, Irene

The growing scarcity of freshwater has intensified the need for alternative water sources, which often require advanced treatments to eliminate contaminants. Among emerging pollutants, pharmaceuticals have become a significant concern due to their persistence and potential impact, making their detection essential. However, analysing these contaminants is challenging due to the extremely low concentrations at which they are present. For chemical analysis, minimal or no sample enrichment is often necessary, while bioanalysis typically requires larger sample volumes and an enrichment factor to conduct comprehensive bioassays across various endpoints. Consequently, sample preconcentration techniques for large water volumes are necessary to improve the sensitivity of subsequent toxicological experiments. In this study, a novel large volume solid-phase extraction (LV-SPE) procedure was validated and evaluated for monitoring multiple pharmaceutical compounds in water samples, while maintaining the traditional solid-phase extraction (SPE) methodology using cartridges. This method proved effective extraction and preconcentration of significant amounts of water, with recoveries between 19 % and 109 % in spiked wastewaters (except for fluvoxamine, remdesivir, tamoxifen and tetracycline, with recoveries <10 %). Furthermore, the optimization of this approach covers an expansive chemical space, enabling the capture of a diverse range of pharmaceutical compounds and enhancing the validity of toxicological studies. Bioassays conducted with Daphnia magna juveniles and Danio rerio embryos validated the method's applicability regarding optimized exposure conditions, the absence of adverse effects from SPE blanks or solvent controls and sensitivity in detecting effects across field samples. Overall, the LV-SPE approach enhances sensitivity and reliability for evaluating pharmaceutical mixtures' risks under realistic conditions.

01 Sep 2025·Journal of Vascular Surgery-Venous and Lymphatic Disorders

The role of venoactive compounds in the treatment of chronic venous disease

Review

Author: Nicolaides, Andrew ; Gloviczki, Monika Lecomte ; Kakkos, Stavros K ; Chuback, John ; Urbanek, Tomasz

BACKGROUND:

Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation. This review focuses on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim was to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and noninterventional therapies such as compression.

METHODS:

The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema, and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the GRADE methodology from A (high), B (moderate), to C (low to very low) quality.

RESULTS:

Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, and heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and Ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers, micronized purified flavonoid fraction, sulodexide, and pentoxifylline were the most effective adjunctive treatments, with evidence level A.

CONCLUSIONS:

The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and noninterventional approaches like compression, to optimize patient outcomes and improve quality of life.

News (Medical) associated with Pentoxifylline

26 Jun 2025

·www.einpresswire.com

Pentoxifylline Fails to Improve Survival in Alcohol-Associated Hepatitis with Kidney Injury

Researchers found no significant benefit in short- or long-term mortality outcomes with pentoxifylline use. CHINA, June 26, 2025 / EINPresswire.com / -- Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis. Corticosteroids are currently the only treatment shown to offer a modest short-term survival benefit in selected patients. Pentoxifylline, a phosphodiesterase inhibitor with anti-tumor necrosis factor alpha (TNF-α) properties, has been proposed as a potential alternative, especially for patients with contraindications to steroids or coexisting AKI. However, evidence supporting its efficacy has been inconsistent and regionally variable. To clarify the clinical utility of pentoxifylline in this setting, Idalsoaga et al. conducted a retrospective, multicenter registry study across 20 centers from eight countries. The study was published in eGastroenterology . The study included 525 patients diagnosed with sAH and AKI between 2009 and 2019. The primary outcome was all-cause mortality, with liver transplantation considered as a competing event. Main results include: (1) Survival rates at 90 days were 46.2% in the pentoxifylline group versus 49.8% in the control group. (2) Multivariable Cox regression showed that pentoxifylline use was not significantly associated with improved survival. (3) Key predictors of mortality were: older age, higher MELD score at admission, and requirement for renal replacement therapy. In addition, a secondary exploratory analysis focusing on patients with serum creatinine ≥1.5 mg/dL reaffirmed these findings. Again, pentoxifylline use did not improve survival at any time point, including 30, 90, or 180 days. The results of this large real-world cohort study confirm that pentoxifylline offers no mortality benefit in sAH patients with concurrent AKI. This is consistent with previous studies and meta-analyses that have cast doubt on the efficacy of pentoxifylline in alcoholic hepatitis overall. Although pentoxifylline has shown renal protective effects in animal models and other clinical contexts (e.g., diabetic nephropathy, cardiac surgery), these mechanisms may not sufficiently counteract the complex inflammatory and hemodynamic disturbances seen in sAH with AKI. The high rates of multiorgan failure and infection-related deaths in this cohort highlight the multifactorial pathogenesis of mortality in these patients. This study stands out for its large, diverse international cohort, and rigorous statistical approach. However, the retrospective design introduces inherent limitations such as missing data and potential confounding. Nearly half of the records lacked infection data, and the precise timing, dosing, and duration of pentoxifylline therapy were unavailable, which should be explored in the future. The clear absence of benefit from pentoxifylline suggests a pressing need for novel therapies in sAH, particularly for those with AKI who are often excluded from corticosteroid treatment. Potential strategies may include: (1) Targeting specific inflammatory pathways (e.g., IL-1, gut-liver axis); (2) Microbiota-modulating interventions; (3) Plasma exchange; (4) Trials of combination therapy (e.g., corticosteroids + novel agents). Moreover, early detection of renal dysfunction and proactive infection management remain critical components of supportive care. In conclusion, pentoxifylline does not improve survival in patients with sAH and AKI. These findings challenge current regional practices where pentoxifylline remains in use and underscore the need to re-evaluate its role in clinical guidelines. Future research should pivot toward novel, mechanism-based therapies to address the unmet needs of this high-risk population. *** About eGastroenterology eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come! For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ). Menghan Gao eGastroenterology +86 431 8878 2545 egastro@jlu.edu.cn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Result

30 Apr 2024

·www.biospace.com

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's Disease Novel therapeutic with Fast Track and Orphan Designation LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease. Key Highlights 12-month option agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Pentoxifylline (tPTX), a treatment for oral ulcers in patient's suffering from Behçet's Disease which currently has no cure Phase 2 trial successfully completed, demonstrating superiority over standard of care Secured Orphan Drug Designation and Fast Track Designation from the FDA Positioned for a potential 505(b)(2) approval pathway in the U.S. Poolbeg will continue due diligence throughout the term of the exclusive option agreement which will include engagement with Silk Road Therapeutics to ascertain the clinical approval pathway There is a clear unmet medical need for an effective treatment for this rare disease, which has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impact essential functions like eating, drinking and speaking.[1] Patients also suffer from reduced psychosocial quality of life[2]. Current standard of care is inadequate with safety concerns and there is a clear need for alternative treatment options. The topical formulation of PTX, a small molecule with broad anti-inflammatory activity, has successfully demonstrated accelerated oral ulcer healing and decreased pain compared to standard of care in patients with Behçet's Disease in a Phase 2 clinical trial. The drug is positioned for a potential 505(b)(2) approval pathway in the U.S. which can result in a much less expensive and much faster route to approval and commercialisation. tPTX has successfully secured FDA Fast Track Designation, designed to expedite development and review of certain medicines. It has also received Orphan Drug Designation from the FDA, providing seven years of market exclusivity upon marketing authorisation. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "The foundation of any pharma company is a strong pipeline of assets, and we believe that topical PTX could fit well into our pipeline alongside our other assets as we increase our focus on rare and orphan diseases. "We are delighted to enter this exclusive option agreement with Silk Road Therapeutics and Dr Timothy Coté, whose extensive experience, including as Director of the FDA Office of Orphan Products Development, adds invaluable insights into the regulatory pathway and ultimate approval and commercialisation of the drug. "tPTX has the potential to transform the lives of patients suffering from Behçet's Disease, who currently lack effective and safe long term treatment options. Under this exclusive option agreement, we will advance our due diligence process and engage with Silk Road Therapeutics to further understand the clinical pathway to approval, and we look forward to updating the market in due course." Timothy R. Coté, M.D., M.P.H., Chief Executive Officer of Silk Road Therapeutics, said: "Poolbeg Pharma shares our commitment to advancing healthcare innovation to support rare disease patients. With Fast Track Designation and Orphan Drug Designation secured, topical PTX has the potential to swiftly reach patients and offer a potentially transformative solution for those suffering from Behçet's Disease." Investor presentation Poolbeg Pharma CEO, Jeremy Skillington, PhD, and CBO David Allmond, along with Dr Timothy Coté, CEO of Silk Road Therapeutics,will provide a live presentation via the Investor Meet Company platform on Tuesday 30 April 2024 at 6pm BST. The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard via: Enquiries Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO +44 (0) 207 183 1499 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) +44 (0) 207 220 0500 Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher +44 (0) 207 496 3000 J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363 Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Elena Bates +44 (0) 208 078 4357 poolbeg@optimumcomms.com About Behçet's Disease Behçet's Disease is a rare condition that results in inflammation of the blood vessels and tissues. Inflammation across multiple parts of the body leads to diverse symptoms, the most prevalent being recurrent oral ulcers, in addition to genital ulcers and inflammation of the eye and skin lesions. It is not yet known what triggers the disease or causes it to persist. However, it is clear there is a significant immune component with some suggestions that exaggerated responses to pathogens and increased cytokine and chemokine production may play key roles in the disease.[3] About Poolbeg Pharma Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. For more information, please go to or follow us on Twitter and LinkedIn @PoolbegPharma. Forward-Looking Statements This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information. [1] Hatemi G, Yurttas B, Kutlubay Z, Cote T, Derkunt S, Yazici Y, Yazici H. Pentoxifylline Gel for Oral Ulcers in Patients with Behçet's Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). . Accessed April 17, 2024. [2] Ali S, Nagieb CS, Fayed HL. Effect of Behcet's disease-associated oral ulcers on oral health related quality of life. Spec Care Dentist. 2023 Jul-Aug;43(4):435-442. doi: 10.1111/scd.12782. Epub 2022 Sep 20. PMID: 36127751. [3] behcetsuk.org This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Poolbeg Pharma PLC View the original press release on accesswire.com

Orphan DrugFast TrackPhase 2Clinical ResultDrug Approval

24 Jan 2024

·www.globenewswire.com

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Jan. 23, 2024 -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD) Trental®. The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. “We are pleased to continue the momentum in our generics business with another launch into a limited competition market. ANI remains committed to driving growth through superior new product launch execution, operational excellence, cost-competitiveness, and supply reliability. With a patient-first mindset, our goal is to ensure that patients in need, and the providers who care for them, have access to our high-quality therapeutics,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com. The content above comes from the network. if any infringement, please contact us to modify.

100 Deals associated with Pentoxifylline

External Link

KEGG	Wiki	ATC	Drug Bank
D00501	Pentoxifylline	C04AD03	DB00806

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Intermittent Claudication	Australia	Clinect Pty Ltd.	14 Dec 2001
Peripheral arterial occlusive disease	United States	Validus Pharmaceuticals LLC	30 Aug 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Behcet Syndrome	Phase 2	United Kingdom	Poolbeg Pharma Plc	30 Apr 2024
Asthenozoospermia	Phase 2	Spain	-	08 May 2017
Acquired Immunodeficiency Syndrome	Phase 1	United States	Hoechst Marion Roussel, Inc.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05708248 (Pubmed \| Postgrad Med)	Not Applicable	Anemia \| Hemodialysis complication HIF-2α \| TGF-β1 \| hs.CRP	80	Pentoxifylline 400 mg	ugfadfizzj(upxynntjzw) = dldjkqnzqu oktlceosyp (ucucsdahwm, 2.01 - 10.09) View more	Positive	10 Nov 2024
NCT02592863 (CTgov)	Not Applicable	Vertigo \| Dizziness \| Equilibration disorder	26	Pentoxifylline (Pentoxifylline)	rgguyflljr(vwmctnjhuj) = tumyirezfm auuonuxcgo (farklkrfde, 16.236) View more	-	15 Oct 2024
				Placebo (Placebo)	rgguyflljr(vwmctnjhuj) = slavplmops auuonuxcgo (farklkrfde, 22.825) View more
NCT02451774 (Pubmed \| Front Oncol)	Phase 2/3	Acute Lymphoblastic Leukemia	-	Pentoxifylline	olsetaidli(ccfbpodrrm) = gcyfejciqs zzlhhgepzc (wcvoxdgjvb ) View more	Positive	03 Oct 2024
				Placebo	olsetaidli(ccfbpodrrm) = nfcaowcmom zzlhhgepzc (wcvoxdgjvb ) View more
NCT05487755 (Pubmed) Manual	Phase 3	Diabetic Nephropathies Adjuvant	90	Tadalafil 20 mg	utxztcgwec(xsmfqsoibn) = tzhibfdtxg twtswcyafp (gupxltkujd )	Positive	24 Jun 2024
				Pentoxifylline 400 mg	utxztcgwec(xsmfqsoibn) = ejtnvvbehn twtswcyafp (gupxltkujd )
NCT01774487 (CTgov)	Phase 2	Biliary Atresia	17	Pentoxifylline (Pentoxifylline - Group 1)	djiyinimtf = srzddkfhul crtgboksnt (kchlrqbczt, whqufaffqk - xepdzpzfch) View more	-	12 Oct 2023
				Pentoxifylline (Pentoxifylline - Group 2)	djiyinimtf = wvqmsnbptb crtgboksnt (kchlrqbczt, guildesgnu - dpdunwriav) View more
ASTRO2023	Not Applicable	Pneumonia	-	Pentoxifylline and Vitamin E	mfzsihywer(tkkkiiujiy) = skcwxomlwn wemwnvvgtt (vonlwpsjor )	-	01 Oct 2023
NCT01508221 (CTgov)	Phase 2	Radiation Injuries \| Brain metastases	31	Vitamin E+Trental	bvkzbghkuz = ddfajajrkw ksphfjyplr (kzwlxtwmyx, nlrcxztwok - ejadxxzjfq) View more	-	14 Sep 2023
NCT03830164 (CTgov)	Phase 2	Erectile Dysfunction \| Adenocarcinoma of prostate	14	statin+Atorvastatin+Pentoxyfilline+Vitamin E (Cohort 1)	tzcegtbwcx = vzmbgugukk hzwtviugtb (szjohfhixb, vttplrbosq - uyhvxophbi) View more	-	03 Apr 2023
				Atorvastatin+Pentoxyfilline+Vitamin E (Cohort 2)	tzcegtbwcx = tdfhrsfdca hzwtviugtb (szjohfhixb, dydlubtygj - xrqazwmwyz) View more
RTHP-01 (SNO2019)	Not Applicable	-	48	Pentoxifylline + Vitamin E	ckxukptahp(cckofyaiun) = 3 patients stopped Ptx + VitE due to reported side effects lmlmeocdof (mgbzdkayzo )	Positive	11 Nov 2019
ERS2019	Not Applicable	Sarcoidosis TNF	44	Pentoxifylline	lsjxqshdrx(twkmqmdddr) = wdpaqliypu rkvjxykzjj (bppznxagel )	Positive	28 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pentoxifylline

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation